Axsome Therapeutics, Flexion Therapeutics, and UroGen Pharma gave investors reasons for excitement.
News & Analysis: Flexion Therapeutics
FLXN earnings call for the period ending March 31, 2019.
The pharma company announced first-quarter 2019 operating results.
FLXN earnings call for the period ending December 31, 2018.
The company reported preliminary full-year 2018 results and set expectations for a solid year of growth in 2019.
The small-cap biopharma announced third-quarter 2018 operating results and a business update.
There was good news on the payer front.
It could be a make-it-or-break-it kind of year for these up-and-coming biotech companies.
A newly approved drug that could shake up how doctors treat knee pain could be very profit-friendly for investors.
Flexion's non-opioid pain management drug has huge potential, and it's looking to expand into more indications.